Get the Daily Brief
Latest Biotech News
CRISPR Guide RNA Design Shown to Exhibit Ancestry Bias in Cancer Screens
Analysis by Broad Institute researchers revealed that CRISPR-Cas9 guide RNAs used in large-scale genome-wide cancer dependency screens perform unevenly across cell lines derived from different...
Merck Advances Once-Monthly Oral HIV Prevention Pill into Phase 3 Trials
Merck & Co. has initiated Phase 3 studies of MK-8527, an investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). Trials will enroll populations at elevated risk of HIV-1...
Innovative Microbiome-Dendritic Cell Interaction Spurs Antitumor Immunity
A Nature 2025 study identified a novel gut bacterial strain, YB328, that surpasses known commensals in activating and reprogramming bone-marrow-derived dendritic cells (BMDCs), key orchestrators...
Bio-Techne Partners with Spear Bio to Distribute Neurology Biomarker Immunoassays
Bio-Techne announced a strategic collaboration with Spear Bio to distribute its sensitive immunoassays detecting low-abundance neurological biomarkers including phosphorylated tau 217 and 231,...
AstraZeneca's hypertension drug baxdrostat posts positive pivotal trial
AstraZeneca announced successful results from its BaxHTN phase III trial where the aldosterone synthase inhibitor baxdrostat significantly reduced blood pressure in patients with uncontrolled or...
Ultragenyx's gene therapy for Sanfilippo syndrome hits manufacturing setback
Ultragenyx Pharmaceutical received a complete response letter from the FDA due to manufacturing process concerns for its gene therapy UX111 targeting Sanfilippo syndrome type A. While the agency’s...
Takeda scores dual phase III wins with narcolepsy drug oveporexton
Takeda Pharmaceutical announced positive results from two phase III trials of oveporexton, an oral orexin receptor 2 (OX2R)-selective agonist for narcolepsy type 1. The drug met all primary and...
Bio-Techne partners with Spear Bio for ultrasensitive neurology biomarker immunoassays
Bio-Techne entered a strategic partnership to distribute Spear Bio's innovative immunoassays targeting low-abundance neurology biomarkers relevant to Alzheimer's disease research, including...
JCR Pharmaceuticals inks $825M deal with Alexion on AAV capsid platform
JCR Pharmaceuticals signed a license agreement with AstraZeneca’s rare disease unit Alexion to enable use of JCR’s JUST-AAV capsid technology in up to five genomic medicine programs. The deal...
Bird flu remains active and poses ongoing ecological and zoonotic risks
Despite a decline in news coverage, the H5N1 avian influenza virus continues to circulate extensively among wild birds, poultry, marine mammals, and recently dairy cattle across the U.S. Outbreaks...
Innovative bacterial calcification approach offers new Tack Against MRSA
Two complementary studies published in Nature Biotechnology detail novel immunological strategies to combat methicillin-resistant Staphylococcus aureus (MRSA) infections by inducing bacterial...
Microbiome research advances pathogen detection and disease biomarker identification
Recent collaborations and studies highlight breakthroughs in leveraging microbiome and molecular biology for precision diagnostics. The Vienna BioCenter and University of Ghana developed an...
Alpha Tau Medical’s localized alpha radiation therapy triggers systemic anti-cancer immunity
Alpha Tau Medical’s Alpha DaRT treatment employs localized alpha radiation delivered directly into tumors, demonstrating 100% tumor response in early FDA trials across multiple solid tumor types,...
FDA Rejects Ultragenyx Gene Therapy Over Manufacturing Issues
Ultragenyx Pharmaceutical received a complete response letter from the FDA declining approval of its gene therapy UX111 for Sanfilippo syndrome type A, citing manufacturing-related concerns during...
AstraZeneca Advances Hypertension Drug with $1.3B CinCor Deal Paying Off
AstraZeneca’s experimental aldosterone synthase inhibitor baxdrostat demonstrated statistically significant reductions in systolic blood pressure in a phase III trial involving patients with...
Takeda Narcolepsy Drug Oveporexton Scores Double Phase 3 Wins
Takeda’s oral orexin receptor 2-selective agonist oveporexton met all primary and secondary endpoints in two phase III studies for narcolepsy type 1, demonstrating clinically meaningful...
Waters and BD Merge in $17.5B Life Sciences Deal
Waters Corp. has agreed to combine with Becton, Dickinson & Co.'s Biosciences & Diagnostics Solutions business in a transaction valued at $17.5 billion, marking the largest life sciences deal of...
Integrated Optogenetics Platform Uncovers New Antiviral Compounds
Integrated Biosciences has developed a novel optogenetic screening platform enabling precise control and high-throughput interrogation of biological systems, facilitating discovery of selective...
Alzheimer’s Biomarkers via Circular RNA and Proteomics in Depression Patients
Researchers at Washington University and Circular Genomics have identified circular RNA (circRNA) biomarkers, including circHOMER1, associated with Alzheimer’s disease diagnosis and progression....
Innovations in Personalized Cancer Therapeutics Manufacturing
Elegen and Nutcracker Therapeutics have partnered to pilot a fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapies. The combined approach addresses...